AR and breast cancer: Notably, a phase Ib clinical trial of alpelisib plus enzalutamide for treating AR and PTEN-positive metastatic BC patients is ongoing, which may provide clinical evidence for the combination of AR and PI3Kα inhibitors in managing advanced TNBC (ClinicalTrials.gov Identifier: NCT03207529) (Table 1).